An interventional study of Physiotherapy and Pain Neuroscience Education in Temporomandibular Joint Disorders, sponsored by Ainaz Shahedi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Ainaz Shahedi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Temporomandibular Joint Disorders with a site in Turkey — 27 open to participants now, 28 under way, none of them phase 3. Temporomandibular Joint Disorders · Turkey.
Among the 151 studies in Temporomandibular Joint Disorders with a site in Turkey, this one is the 43rd largest by enrollment of the 81 interventional ones that give a count, is one of 21 that started in 2025, is one of 77 with no phase, and was the 109th registered.
593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →27 of the 151 studies in Temporomandibular Joint Disorders with a site in Turkey are open now. Recruiting first, the newest first:
Mustafa Kemal University · Sites in Turkey
Ages 35–75 · Healthy volunteers
sevilay seda bas · Sites in Turkey
Ages 18–55
Yuzuncu Yil University · Sites in Turkey
Ages 18–65
Uşak University · Sites in Turkey
Ages 18–65
Recep Tayyip Erdogan University · Sites in Turkey
Ages 18+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is close to the median of 45 across 417 interventional studies indexed under Temporomandibular Joint Disorders.
Median enrollment 45 across the 81 interventional studies, 78 across the 70 observational. Of the 115 that completed or were terminated, 4 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 151 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ainaz Shahedi as lead sponsor.
Ainaz Shahedi has 1 study filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Temporomandibular Joint Disorders with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07577687Yuzuncu Yil UniversityEffect of Emg-Biofeedback and Multimodal Exercise on Temporomandibular Joint Dysfunction | 2026-12-15 |
| NCT07850674Mustafa Kemal UniversitySpinal Mobility, Rigidity, and Kinesiophobia in PD and TMD | 2026-12-23 |
| NCT07576582Uşak UniversityPeloid Therapy in Temporomandibular Joint Dysfunction | 2027-01-01 |
| NCT07791173Zeynep Serra KalkanEvaluation of Temporomandibular Disorders During Pregnancy | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 151 studies in Temporomandibular Joint Disorders with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study aims to evaluate the effectiveness of Pain Neuroscience Education (PNE) when it is added to a physiotherapy program for people experiencing chronic temporomandibular disorders (TMD). To see whether adding PNE to physiotherapy program would provides additional benefits in reducing pain intensity, improving psychological well-being, and enhancing functional outcomes. The findings are expected to provide new insights into more comprehensive and patient-centered treatment strategies for managing chronic TMD.
Participants will be randomly assigned to one of two groups:
Control Group: Physiotherapy only
PNE Group: Physiotherapy plus Pain Neuroscience Education
Both groups will receive their respective treatments for a set period of time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Physiotherapy
Behavioral: Pain Neuroscience Education
Physiotherapy treatment programs include therapeutic ultrasound, muscle relaxation techniques, range of motion exercises, and joint and soft tissue mobilization.
PNE sessions will be conducted in addition to physiotherapy programs for intervention groups. PNE sessions will occupy half of each session during the first two weeks. Physiotherapists trained in PNE will deliver sessions using a combination of metaphors, animated videos, and scientifically accurate descriptions. The same physiotherapist will lead both sessions with the same patient. Active learning techniques will include: Connecting new information with prior knowledge. Operationalizing key pain concepts into individual contexts. Facilitated problem-solving and critical reflection.
The Craniofacial Pain and Disability Inventory (CF-PDI)
It consists of 21 items, with a score ranging from 0 to 63 points. Each question is scored on a 4-point ordinal scale, ranging from 0 to 3. A higher score reflects higher disability levels.
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
Numeric Pain Rating Scale (NPRS)
It includes an 11-point numerical rating scale, ranging from 0, indicating (no pain), to 10, representing (the worst pain imaginable),.
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
Pain Self-Efficacy Questionnaire (PSEQ)
It consists of 10 items scored on a 7-point ordinal scale (ranging from 0: "not at all confident" to 6: "completely confident").
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
Pain Catastrophizing Scale (PCS)
It consists of 13 items for the assessment of catastrophizing thoughts. It is divided into three domains: helplessness, magnification, and rumination. Each item is scored on a 5-point ordinal scale. The PCS total score ranges from 0 to 52 points, higher values denote greater pain catastrophizing.
Time frame: Baseline,1 month after start of treatment, Immediate post-treatment, 3 month follow up
Hospital Anxiety and Depression Scale (HADS)
It comprises two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D), each consisting of seven items distributed throughout the questionnaire. Every item is rated on a 4-point Likert scale ranging from 0 to 3, reflecting the severity of symptoms. A score of 8 or above on either subscale is considered indicative of possible anxiety or depression.
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
The Tampa Scale for Kinesiophobia specific to Temporomandibular Disorders (TSK-TMD)
It consists of 12 items. Each item is scored on a 4-point ordinal scale, ranging from "strongly disagree" (score = 1) to "strongly agree" (score = 4). Ratings are summed to yield a total score. Higher scores reflect a greater fear of movement (12-48 points).
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
Revised Neurophysiology of Pain Questionnaire (rNPQ)
It includes 12 items, each requiring a true, false, or undecided response. Each correct answer receives one point, while incorrect or undecided answers receive zero. Total scores range from 0 to 12, with higher scores reflecting greater knowledge of pain-related physiological concepts.
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
The Exercise Adherence Rating Scale (EARS)
The tool consists of six items rated on a five-point Likert scale, ranging from 0 (strongly agree) to 4 (totally disagree). Items with positively worded statements are reverse-scored to maintain consistency in interpretation. The total adherence score ranges from 0 to 24, with higher scores indicating greater adherence to the exercise regimen.
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
Fear Avoidance Components Scale (FACS)
This self-administered questionnaire comprises 20 items rated on a 6-point Likert scale, ranging from 0 (completely disagree) to 6 (completely agree), yielding a maximum score of 100. Higher scores indicate stronger fear-avoidance beliefs.
Time frame: Baseline, 1 month after start of treatment, Immediate post-treatment, 3 month follow up
Plan to share: No — At present, there is no plan to share individual participant data (IPD) outside the research team due to the small sample size and confidentiality considerations. However, in the future, de-identified data may be shared if required by institutional policy, journal requirements, or upon reasonable request from qualified researchers, always in accordance with ethical and legal standards.
Ran from Jun 2025 to primary completion in Jun 2026, 12 months.
Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's 12 months is close to that.
Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.
Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Jun 2025, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →